Title Alternative Epidemiological characteristics of novel coronavirus infection in Okayama Prefecture
FullText URL 133_43.pdf
Author Higashionna, Tsukasa| Sendo, Toshiaki| Kusano, Nobuchika| Tsukahara, Hirokazu|
Keywords 疫学的調査 (epidemiological characteristics) 岡山 (Okayama Prefecture) 新型コロナウイルス感染症 (COVID-19) PCR検査 (PCR testing) SARS-CoV-2
Publication Title Journal of Okayama Medical Association
Published Date 2021-04-01
Volume volume133
Issue issue1
Start Page 43
End Page 48
ISSN 0030-1558
Related Url isVersionOf https://doi.org/10.4044/joma.133.43
language Japanese
Copyright Holders Copyright (c) 2021 岡山医学会
File Version publisher
DOI 10.4044/joma.133.43
NAID 130008034824
Title Alternative Drug interaction (50. Drug interaction mediated transporters)
FullText URL 133_68.pdf
Author Manabe, Yohei| Esumi, Satoru| Sendo, Toshiaki|
Publication Title Journal of Okayama Medical Association
Published Date 2021-04-01
Volume volume133
Issue issue1
Start Page 68
End Page 72
ISSN 0030-1558
Related Url isVersionOf https://doi.org/10.4044/joma.133.68
language Japanese
Copyright Holders Copyright (c) 2021 岡山医学会
File Version publisher
DOI 10.4044/joma.133.68
NAID 130008034821
JaLCDOI 10.18926/AMO/63410
FullText URL 76_2_167.pdf
Author Higashionna, Tsukasa| Ushio, Soichiro| Esumi, Satoru| Murakawa, Kiminaka| Kitamura, Yoshihisa| Sendo, Toshiaki|
Abstract Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN.
Keywords febrile neutropenia cefozopran cefepime lung cancer retrospective
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2022-04
Volume volume76
Issue issue2
Publisher Okayama University Medical School
Start Page 167
End Page 172
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders Copyright Ⓒ 2022 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 35503444
Web of Science KeyUT 000792374900008
FullText URL fulltext.pdf
Author Ushio, Soichiro| Wada, Yudai| Nakamura, Mizuki| Matsumoto, Daiki| Hoshika, Kota| Shiromizu, Shoya| Iwata, Naohiro| Esumi, Satoru| Kajizono, Makoto| Kitamura, Yoshihisa| Sendo, Toshiaki|
Keywords anxiolytic inflammation immunomodulation macrophages Kampo medicine
Published Date 2022-08-12
Publication Title Frontiers In Pharmacology
Volume volume13
Publisher Frontiers Media S.A.
Start Page 890048
ISSN 1663-9812
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2022 Ushio, Wada, Nakamura, Matsumoto, Hoshika, Shiromizu, Iwata, Esumi, Kajizono, Kitamura and Sendo.
File Version publisher
PubMed ID 36034871
DOI 10.3389/fphar.2022.890048
Web of Science KeyUT 000860773600001
Related Url isVersionOf https://doi.org/10.3389/fphar.2022.890048